Patents by Inventor Masaki Kiga

Masaki Kiga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10139415
    Abstract: Provided are: a method of predicting sensitivity to a molecularly targeted drug; a method of selecting a patient who is determined to have high responsiveness to administration of a drug; and a reagent to be used in these methods.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: November 27, 2018
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Masaki Kiga
  • Patent number: 9751887
    Abstract: The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: September 5, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yasuyuki Takeda, Kenji Yoshikawa, Yoshiko Kagoshima, Yuko Yamamoto, Ryoichi Tanaka, Yuichi Tominaga, Masaki Kiga, Yoshito Hamada
  • Publication number: 20160046639
    Abstract: The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 18, 2016
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yasuyuki Takeda, Kenji Yoshikawa, Yoshiko Kagoshima, Yuko Yamamoto, Ryoichi Tanaka, Yuichi Tominaga, Masaki Kiga, Yoshito Hamada
  • Publication number: 20160011201
    Abstract: Provided are: a method of predicting sensitivity to a molecularly targeted drug; a method of selecting a patient who is determined to have high responsiveness to administration of a drug; and a reagent to be used in these methods.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 14, 2016
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Masaki KIGA
  • Patent number: 9187489
    Abstract: The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: November 17, 2015
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yasuyuki Takeda, Kenji Yoshikawa, Yoshiko Kagoshima, Yuko Yamamoto, Ryoichi Tanaka, Yuichi Tominaga, Masaki Kiga, Yoshito Hamada
  • Publication number: 20150051190
    Abstract: The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.
    Type: Application
    Filed: June 3, 2013
    Publication date: February 19, 2015
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yasuyuki Takeda, Kenji Yoshikawa, Yoshiko Kagoshima, Yuko Yamamoto, Ryoichi Tanaka, Yuichi Tominaga, Masaki Kiga, Yoshito Hamada